【摘要】 肥胖和食物成瘾已经成为危害人民群众健康的重要因素，其交互作用加剧代谢异常及并发症风险。胰高血糖素样肽-1受体激动剂(GLP-1RA)已成为治疗肥胖和食物成瘾的有利选择，其治疗机制也逐渐成为研究的热点和重点。研究表明，GLP-1RA通过中枢与外周机制抑制食欲、延缓胃排空，并作用于中脑边缘多巴胺系统，减少伏隔核多巴胺释放，削弱高热量食物的奖赏效应，从而改善食物成瘾行为，进一步治疗肥胖。然而，GLP-1RA的胃肠道不良反应及潜在长期风险仍需谨慎管理。文章就GLP-1RA治疗肥胖以及食物成瘾的临床研究进展进行综述，为肥胖和食物成瘾的药物选择提供参考。

    【关键词】 胰高血糖素样肽-1受体激动剂；肥胖；食物成瘾；中脑边缘多巴胺系统

    Mechanism of glucagon-like peptide-1 receptor agonist in the treatment of obesity and food addiction

    LIU Luyao， LI Linwei， WANG Chen， DI Jianzhong

    (Department of Weight Loss and Metabolism， Shanghai Sixth People’ s Hospital， Shanghai 201306， China)

    Corresponding author： DI Jianzhong， E-mail： dijianzhong@stju.edu.cn

    【Abstract】 Obesity and food addiction have become major threats to public health， and their synergistic interactions exacerbate metabolic abnormalities and comorbidities. Glucagon-like peptide-1 receptor agonist (GLP-1RA) has emerged as a promising therapeutic option for these conditions， and their mechanism of action has become a major research focus. Evidence indicates that GLP-1RA suppress appetite and delay gastric emptying through central and peripheral pathways. Furthermore ......